Excellent report. The company still describes itself as "clinical Stage".
Value catalysts -
"The senior leadership team will continue to explore partnership opportunities with global pharmaceuticalcompanies, as we expect the unique attributes of the proprietary ddRNAi approach and the breadth ofpotential clinical applications to support the formation of additional collaborations over a broad range ofdisorders with significant unmet medical need."
To date, this strategic review has yielded several putative biological targets and clinical indications that bear furtherevaluation, and the scientific team is working to complete the requisite analytical processes to support the productionof comprehensive research plans for each potential program prior to final target selection and approval by the seniorleadership team and the Board of Directors.
"The Company is seeking partnerships to support the progression of BB-103 into the clinic"
BLT Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
